Table 1 Baseline demographics and clinical characteristics of patients with wild-type KRAS metastatic colorectal cancer included in the EQ-5D HSI and EQ-5D VAS from two trials of panitumumab
First-line trial | Second-line trial | |||
|---|---|---|---|---|
Panitumumab + FOLFOX4 ( n =284) | FOLFOX4 ( n =292) | Panitumumab + FOLFIRI ( n =263) | FOLFIRI ( n =267) | |
Male, n (%) | 189 (66.5%) | 186 (63.7%) | 159 (60.5%) | 171 (64.0%) |
Age, mean years (s.d.) | 60.5 (10.5) | 60.1 (11.3) | 60.1 (10.1) | 60.6 (10.1) |
White race, n (%) | 257 (90.5%) | 271 (92.8%) | 255 (97.0%) | 253 (94.8%) |
Region, n (%) | ||||
Australia, USA, western Europe, Canada | 166 (58.5%) | 161 (55.1%) | 162 (61.6%) | 163 (61.0%) |
Rest of world | 118 (41.5%) | 131 (44.9%) | 101 (38.4%) | 104 (39.0%) |
ECOG performance status, n (%) | ||||
0–1 | 270 (95.1%) | 276 (94.5%) | 253 (96.2%) | 255 (95.5%) |
⩾2 | 14 (4.9%) | 16 (5.5%) | 10 (3.8%) | 12 (4.5%) |
Primary tumour type, n (%) | ||||
Colon | 183 (64.4%) | 192 (65.8%) | 160 (60.8%) | 171 (64.0%) |
Rectal | 101 (35.6%) | 100 (34.2%) | 103 (39.2%) | 96 (36.0%) |
Site of metastatic disease, n (%) | ||||
Liver only | 53 (18.7%) | 48 (16.4%) | 56 (21.0%) | 46 (17.5%) |
Liver+other | 193 (68.0%) | 199 (68.2%) | 169 (63.3%) | 178 (67.7%) |
Other only | 37 (13.0%) | 44 (15.1%) | 40 (15.0%) | 39 (14.8%) |
Missing or unknown | 1 (0.4%) | 1 (0.3%) | 2 (0.7%) | 0 (0.0%) |
Prior therapy, n (%) | ||||
Oxaliplatin | NA | NA | 175 (66.5%) | 172 (64.4%) |
Bevacizumab | NA | NA | 49 (18.6%) | 55 (20.6%) |
Baseline EQ-5D HSI | ||||
Mean (s.d.) | 0.778 (0.247) | 0.756 (0.244) | 0.769 (0.230) | 0.762 (0.252) |
Baseline EQ-5D VAS | ||||
Mean (s.d.) | 74.1 (19.3) | 70.1 (20.8) | 73.3 (17.3) | 71.9 (18.8) |
